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Capillary Leak Syndrome in the Pediatric Population:
Incidence, Risk Factors and Prognostic Value
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Capillary leak syndrome (CLS) is complication occurring after
stem cell transplantation (SCT), which consists in a loss of
intravascular ﬂuids into interstitial spaces after endothelial
damage. CLS incidence is around 20% among adults, and so
far unknown in the pediatric population. Risk factors for CLS
are the use of G-CSF as well as the burden of pre-transplant
chemotherapy. We aimed at assessing CLS incidence, risk
factors and impact on survival in a pediatric cohort of
patients.
In this single centre, retrospective study we revised the
clinical charts of all the patients<18 years of age undergoing
SCT between January 2002 and May 2012 at our Institution.
CLS was deﬁned by at least the ﬁrst 2 of the following
criteria: weight gain>3% in 24 hours, positive intake balance
irrespective of diuretic administration, oedemas (ascites,
pleural effusion, pericarditis, peripheral oedema), hypoten-
sion (10% reduction of MAP), hypoalbuminemia
Clinical data were collected in an electronic database.
235 patients underwent 276 SCT procedures in the analyzed
timeframe.
15/276 fulﬁlled criteria for CLS diagnosis (5.4%).
Patients’ characteristics, conditioning regimen, donor type,
stem cell source, CSA administration as GvHD prophylaxis
and G-CSF administration did not represent a risk factor for
CLS.
The probability of developing CLS was signiﬁcantly higher in
patients exhibiting sepsis (14.3% vs 0.6 %,p< 0.01), and pa-
tients developing CLS were at higher risk for developing
acute GvHD in the ﬁrst 30 days after SCT (10.8% vs 1.8%
p<001).
10/15 patients exhibiting CLS required intensive care
treatment.
In 9 patients CLS did not resolve and directly led to death.
CLS deeply impacts on overall survival on day + 100 after
transplantation (pOS 92.3% vs 57.1%, p<0.01), being a strong
predictive factor for day + 100 TRM.
The CLS is an uncommon but severe complication in pedi-
atric SCT recipients.
No pre-transplant risk factors for CLS could be identiﬁed in
our study. Among the post transplant complications, sepsis is
signiﬁcantly associated with the appearance of CLS. Patients
who develop CLS often need an intensive care treatment and
are at high risk for early TRM, as well as for other endothe-
lium derived complications like GvHD.
The biological relation between sepsis, GvHD and CLS
development in terms of cytokine release and endothelial
damage is worth further studies in order to possibly support
new targeted therapies.
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Introduction: Hematopoietic stem cell transplantation
(HSCT) is the deﬁnitive treatment for some primary immu-
nedeﬁciencies (PID). In 2010 all the pediatric HCT Centers in
Mexico formed the “Mexican Association of Pediatric Stem
Cell Transplantation and Cellular Therapy”. This represents
the ﬁrst report of the association describing the clinical
outcome in HSCT for PID.
Material and Methods: Between January 1998 to March
2013 all PID patients in whom a HSCT was performed in 7
pediatric HCT centers in Mexico, were retrospectively
analyzed.
Results: A total of 57 patients were included. Average age
was 29 months (range 2 to 158). Time from diagnosis until
transplantation was 20 months (range 1 to 110). Diagnosis
included severe combined immunodeﬁciency in 30% (n¼17),
Wiskott-Aldrich Syndrome in 24% (n¼14), Griscelli-syn-
drome in 10% (n¼6), Shwachman-Diamonn 2% (n¼1), Ché-
diak-Higashi syndrome in 2% (n ¼1), others PIDs (in 32%
n¼18). Graft source included: related bone marrow (RBM) in
7% (n¼4), unrelated cord blood in 72% (n¼41), and mobilized
peripheral blood (PMB), including one haploidentical case, in
21% (n¼12). Median cell dose by settings was as follows: in
RBM median mononuclear cell dose was 2.34x108/kg and
median CD34 cell dose was 2.48x106/kg. In PMB median
nucleated cell dose was 8.6 x108/kg and median CD34 cell
dose was 6.3x106/kg, whereas in UCB Median Nucleated cell
dosewas 2.9x108/kg andmedian CD34 cell dosewas 2.1x106/
kg. In all but 1 case, GVHD prophylaxis was given. Condi-
tioning regimens included myeloablative in 63% of patients
(N¼36) and non-myeloablative in 37% (n¼21). Engraftment
occurred in 63% of patients (n¼36). The average time for
neutrophil engraftment was 20 days (range from 8 to 54).
Fourteen patients (24%) developed an II-IV grades aGVHD,
whereas cGvHD was presented only in 7 cases (12%). Trans-
plant related mortality was 26% considering deaths before
day 100. The main causes of death were infection and graft
failure. Overall survival of all cases was 61%.
Conclusion: This is the ﬁrst report of HSCT for PID children in
Mexico. The mean source of Hematopoietic stem cells used
was UCB (71%) with good results in our population. Early
diagnosis and prompt performance of SCT with an optimal
donor and conditioning regimen contributed to the favorable
outcomes.258
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Figure 1
Disease Name Families
reporting
condition
Families reporting
condition/total
families
responding
Transplant indications
Acute lymphoblastic leukemia 145 0.34%
Hodgkin’s lymphoma 144 0.33%
Non-Hodgkin’s lymphoma 141 0.33%
Sarcoma 73 0.17%
Sickle cell disease 54 0.12%
Acute myelogenous leukemia 42 0.10%
Neuroblastoma 40 0.09%
Beta thalassemia major 38 0.09%
Chronic myelogenous leukemia 37 0.09%
Chronic lymphocytic leukemia 32 0.07%
Severe aplastic anemia 22 0.05%
Multiple myeloma 19 0.04%
Myelodysplastic syndrome 10 0.02%
Diamond-blackfan anemia 6 0.01%
Fanconi anemia 4 0.01%
Hurler syndrome 0 0.00%
TOTAL* 807 1.87%
Regenerative indications
Autism/apraxia 1348 3.12%
Diabetes, type 1 1088 2.52%
Diabetes, type II 1044 2.41%
Inﬂammatory bowel disease 1044 2.41%
Other developmental delay 1023 2.36%
Childhood hearing loss 502 1.16%
Cerebral palsy/periventricular
leukomalacia/hypotonia
348 0.80%
Systemic lupus 192 0.44%
Spinal cord injury 154 0.36%
Traumatic brain injury (post-delivery) 139 0.32%
Hydrocephalus 132 0.31%
Hypoxic-ischemic brain injury 128 0.30%
In-utero brain injury/stroke 109 0.25%
Muscular dystrophy 74 0.17%
Infant lung disease 48 0.11%
TOTAL* 7373 17.04%
Figure 2
Transplant indications where child with stored cord blood does not
have condition
Disease Name Family Family count/
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Most patients with primary immune deﬁciency diseases
(PIDDs) will require a stem cell transplant to cure their
disease. There is, however, no consensus about the best
alternative hemopoietic stem cell donor in the absence of an
HLA-identical source. In particular, there are limited data
comparing the outcomes between PIDD patients receiving
umbilical cord blood transplant (UCBT) versus unrelated
matched stem cell products. Fourteen children, median age 8
months (range, 12 e 20 months) with SCID (n¼11), LAD
(n¼1), reticular dysgenesis (n¼1) or Wiskott-Aldrich syn-
drome (n¼1) received UCBT transplant at our institution
between 2007 and 2013. Five of 14 patients had persistent
viral infections prior to transplant: RSV (n¼2), Parainﬂuenza
3 (n¼1), VZV (n¼1) and Norovirus (n¼1), and 7/14 patients
had requiredmechanical ventilation prior to transplantation.
Seven of 14 patients were 6/6 HLA antigen matched with
their stem cell donor, and 7 were one HLA antigen mis-
matched. All patients received myeloablative conditioning
consisting of busulfan, cyclophosphamide and ﬂudarabine
and one patient also received campath. The median total
nucleated cell dose in the transplant was 10x107/kg (range,
5.9 e 25.4). The median time to neutrophil recovery was 19
days (range, 11-30) and the median time to platelet recovery
was 42 days (range, 27-127). All evaluable patients achieved
full donor chimerism (deﬁned as >95% donor cells in pe-
ripheral blood by day +42). No severe aGVHD or cGvHD has
occurred and only one patient developed grade II aGvHD
(skin). All patients are alive with a median follow up of 2
years (range, 10 days e 6 years). All patients with viral in-
fections at the time of transplant were able to clear the
infection at amedian time of 51 days (range, 44-54) and none
developed signiﬁcant new viral infections after transplant.
ELISPOT analyses of peripheral blood at the time that in-
fections were cleared showed T cell responses against the
pertinent viruses. All evaluable patients have normalization
of their immune defect including adequate B cell function in
SCID patients. Hence, we have shown that UCBT for PIDDs
produces speedy functional engraftment and immune-
reconstitution in the absence of signiﬁcant GvHD, leading to
excellent overall survival. UCBT therefore seems an appro-
priate therapeutic alternative for patients with PIDDs who
lack an HLA matched related donor.count total families
responding
Hodgkin’s lymphoma 142 0.33%
Non-Hodgkin’s lymphoma 137 0.32%
Acute lymphoblastic leukemia 110 0.25%
Sarcoma 66 0.15%
Sickle cell disease 49 0.11%
Acute myelogenous leukemia 39 0.09%
Beta thalassemia major 37 0.09%
Chronic myelogenous
leukemia
37 0.09%
Chronic lymphocytic leukemia 31 0.07%
Neuroblastoma 24 0.06%
Severe aplastic anemia 19 0.04%
Multiple myeloma 18 0.04%
Myelodysplastic syndrome 9 0.02%
Diamond-blackfan anemia 6 0.01%
Fanconi anemia 3 0.01%
Hurler syndrome 0 0.00%
TOTAL* 727 1.68%259
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Background: Little is known about the prevalence of dis-
eases amenable to allogeneic or autologous stem cell in-
fusions among families storing newborn stem cells in private
cord blood banks.
Methods: We surveyed families with at least one child who
had stored newborn stem cells at the largest private cordblood bank in the US. We requested that they complete a
Family Health Questionnaire to determine whether a child
with stored stem cells or a ﬁrst degree relative of that child
currently had one or more of 16 diseases or conditions
amenable primarily to allogeneic stem cell transplant
